Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aktis Oncology, Inc.AKTS · Entity 4711 | 10% owner | January 12, 2026 | January 14, 2026 |
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | 10% owner · Former Director | December 31, 2021 | February 10, 2023 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | 10% owner | September 21, 2020 | September 23, 2020 |
| Harpoon Therapeutics, Inc.HARP · Entity 11424 | 10% owner | May 28, 2021 | June 02, 2021 |
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Director · 10% owner | July 28, 2022 | August 01, 2022 |
| Oncorus, Inc.ONCR · Entity 112213 | 10% owner | October 06, 2020 | October 08, 2020 |
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | 10% owner | October 10, 2017 | October 11, 2017 |
| Radius Health, Inc.RDUS · Entity 124173 | Director | February 17, 2017 | February 22, 2017 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | 10% owner | July 09, 2021 | July 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aktis Oncology, Inc.
Report date January 12, 2026 · Filed January 14, 2026
Jointly reported with MPM ASSET MANAGEMENT LLC, Oncology Impact Private Investment Fund 2, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,655,971 |
Reported balance
After 2026-01-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-01-12 · Conversion · Acquired 1,314,262 · Balance 1,655,971 F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,570,168 |
Reported balance
After 2026-01-12 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-01-12 · Conversion · Acquired 5,914,197 · Balance 7,570,168 F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 9,147,287 |
Reported balance
After 2026-01-12 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-01-12 · Conversion · Acquired 1,577,119 · Balance 9,147,287 F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,260,064 |
Reported balance
After 2026-01-12 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-01-12 · Purchase · Acquired 1,112,777 · Balance 10,260,064 F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F10: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact. |
| Series Seed Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-01-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-12 · Conversion · Disposed 5,000,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-01-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-12 · Conversion · Disposed 22,500,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-01-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-12 · Conversion · Disposed 6,000,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact.
F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.
F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F4: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM.
F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.
F6: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.
F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.
F8: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.
F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact.
F10: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.
Cullinan Therapeutics, Inc.
Report date December 31, 2021 · Filed February 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 595,489 |
Reported balance
After 2021-12-21 transaction · row 1
1 source rowRow 1 · 2021-12-21 · Exercise / conversion · Acquired 350,938 · Balance 595,489 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2030-10-28 | Direct | 0 |
Reported balance
After 2021-12-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-21 · Exercise / conversion · Disposed 262,114 · Balance 0 F3: These options are fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2030-10-28 | Direct | 0 |
Reported balance
After 2021-12-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-21 · Exercise / conversion · Disposed 88,824 · Balance 0 F3: These options are fully vested. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,648,268 |
Reported balance
Holding disclosure · report date 2021-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,648,268 F1: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.
F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F3: These options are fully vested.
Dyne Therapeutics, Inc.
Report date September 21, 2020 · Filed September 23, 2020
Jointly reported with MPM BIOVENTURES 2018, L.P., MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, MPM BioVentures 2018 GP LLC, MPM BioVentures 2018 LLC, EVNIN LUKE, Foley Todd
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,614,943 |
Reported balance
After 2020-09-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-09-21 · Conversion · Acquired 4,614,943 · Balance 4,614,943 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 245,279 |
Reported balance
After 2020-09-21 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-09-21 · Conversion · Acquired 245,279 · Balance 245,279 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 91,081 |
Reported balance
After 2020-09-21 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-09-21 · Conversion · Acquired 91,081 · Balance 91,081 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-09-21 · Conversion · Disposed 13,980,992 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-09-21 · Conversion · Disposed 743,076 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-09-21 · Conversion · Disposed 275,932 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-09-21 · Conversion · Disposed 1,326,313 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-09-21 · Conversion · Disposed 70,492 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-09-21 · Conversion · Disposed 26,176 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Harpoon Therapeutics, Inc.
Report date May 28, 2021 · Filed June 02, 2021
Jointly reported with Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC, MPM Oncology Impact Management GP LLC, UBS Oncology Impact Fund L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,374,904 |
Reported balance
After 2021-05-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-05-28 · Sale · Disposed 10,685 · Balance 6,374,904 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,371,804 |
Reported balance
After 2021-05-28 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-05-28 · Sale · Disposed 3,100 · Balance 6,371,804 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,371,704 |
Reported balance
After 2021-05-28 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-05-28 · Sale · Disposed 100 · Balance 6,371,704 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC. F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,353,213 |
Reported balance
After 2021-06-01 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-06-01 · Sale · Disposed 18,491 · Balance 6,353,213 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,328,095 |
Reported balance
After 2021-06-02 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-06-02 · Sale · Disposed 25,118 · Balance 6,328,095 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.
F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC").
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC.
F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Kalaris Therapeutics, Inc.
Report date July 28, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy ElevateBio LLC | 16,674,766 |
Reported balance
After 2022-07-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-07-28 · Grant · Acquired 3,253,796 · Balance 16,674,766 F1: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share. F2: Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 30,197 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 30,197 |
Filing footnotes · ownership attribution and instrument terms
F1: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share.
F2: Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Oncorus, Inc.
Report date October 06, 2020 · Filed October 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,899,702 |
Reported balance
After 2020-10-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-10-06 · Conversion · Acquired 1,783,879 · Balance 1,899,702 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3: The shares are held as follows: 1,382,943 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,239 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,164 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,924 by MPM Sunstates Fund, L.P. ("MPM SunStates"), 33,609 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates") and 115,823 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates. SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Luke Evnin and Anbsert Gadicke are the members of AM LLC and Ansbert Gadicke is a member of SunStates GP. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,525,348 |
Reported balance
After 2020-10-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-10-06 · Conversion · Acquired 1,525,348 · Balance 1,525,348 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,675,677 |
Reported balance
After 2020-10-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-10-06 · Conversion · Acquired 775,975 · Balance 2,675,677 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares are held as follows: 2,018,001 by BV 2014, 134,595 by BV 2014(B), 73,199 by AM BV2014, 290,632 by MPM SunStates, 43,427 by AM SunStates and 115,823 by AM LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,225,801 |
Reported balance
After 2020-10-06 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-10-06 · Conversion · Acquired 700,453 · Balance 2,225,801 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,849,453 |
Reported balance
After 2020-10-06 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2020-10-06 · Purchase · Acquired 173,776 · Balance 2,849,453 F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6: The shares are held as follows: 2,155,108 by BV 2014, 143,740 by BV 2014(B), 78,172 by AM BV2014, 310,251 by MPM SunStates, 46,359 by AM SunStates and 115,823 by AM LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,377,025 |
Reported balance
After 2020-10-06 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-10-06 · Purchase · Acquired 151,224 · Balance 2,377,025 F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-06 · Conversion · Acquired 1,783,879 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7: The shares are held as follows: 1,382,943 by BV 2014, 92,239 by BV 2014(B), 50,164 by AM BV2014, 224,924 by MPM SunStates and 33,609 by AM SunStates. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-10-06 · Conversion · Acquired 1,525,348 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-10-06 · Conversion · Acquired 775,975 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 635,058 by BV 2014, 42,356 by BV 2014(B), 23,035 by AM BV2014, 65,708 by MPM SunStates and 9,818 by AM SunStates. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-10-06 · Conversion · Acquired 700,453 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.
F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F3: The shares are held as follows: 1,382,943 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,239 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,164 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,924 by MPM Sunstates Fund, L.P. ("MPM SunStates"), 33,609 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates") and 115,823 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates. SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Luke Evnin and Anbsert Gadicke are the members of AM LLC and Ansbert Gadicke is a member of SunStates GP.
F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
F5: The shares are held as follows: 2,018,001 by BV 2014, 134,595 by BV 2014(B), 73,199 by AM BV2014, 290,632 by MPM SunStates, 43,427 by AM SunStates and 115,823 by AM LLC.
F6: The shares are held as follows: 2,155,108 by BV 2014, 143,740 by BV 2014(B), 78,172 by AM BV2014, 310,251 by MPM SunStates, 46,359 by AM SunStates and 115,823 by AM LLC.
F7: The shares are held as follows: 1,382,943 by BV 2014, 92,239 by BV 2014(B), 50,164 by AM BV2014, 224,924 by MPM SunStates and 33,609 by AM SunStates.
F8: The shares are held as follows: 635,058 by BV 2014, 42,356 by BV 2014(B), 23,035 by AM BV2014, 65,708 by MPM SunStates and 9,818 by AM SunStates.
RHYTHM PHARMACEUTICALS, INC.
Report date October 10, 2017 · Filed October 11, 2017
Jointly reported with MPM BIOVENTURES V, L.P., EVNIN LUKE, MPM ASSET MANAGEMENT INVESTORS BV5 LLC, MPM BIOVENTURES V GP LLC, MPM BIOVENTURES V LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,596,392 |
Reported balance
After 2017-10-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-10-10 · Conversion · Acquired 2,567,014 · Balance 2,596,392 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F2: The shares are held as follows: 2,499,299 by MPM BioVentures V, L.P. ("BV V") and 97,093 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,696,392 |
Reported balance
After 2017-10-10 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-10-10 · Purchase · Acquired 100,000 · Balance 2,696,392 F3: Shares were purchased as follows: 96,260 by BV V and 3,740 by AM BV5. F4: Shares are held as follows: 2,595,559 by BV V and 100,833 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-10-10 · Conversion · Disposed 7,651,831 · Balance 0 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F5: The shares of Series A Preferred Stock were held as follows: 7,365,688 by BV V and 286,143 by AM BV5. |
| Series A-1 Junior Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-10-10 · Conversion · Disposed 15,887,703 · Balance 0 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F6: The shares of Series A-1 Junior Preferred Stock were held as follows: 15,293,569 by BV V and 594,134 by AM BV5. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date.
F2: The shares are held as follows: 2,499,299 by MPM BioVentures V, L.P. ("BV V") and 97,093 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
F3: Shares were purchased as follows: 96,260 by BV V and 3,740 by AM BV5.
F4: Shares are held as follows: 2,595,559 by BV V and 100,833 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
F5: The shares of Series A Preferred Stock were held as follows: 7,365,688 by BV V and 286,143 by AM BV5.
F6: The shares of Series A-1 Junior Preferred Stock were held as follows: 15,293,569 by BV V and 594,134 by AM BV5.
Radius Health, Inc.
Report date February 17, 2017 · Filed February 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.65 · Expires 2027-02-16 | Direct | 27,500 |
Reported balance
After 2017-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-17 · Grant · Acquired 27,500 · Balance 27,500 F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date.
Repare Therapeutics Inc.
Report date July 09, 2021 · Filed July 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 3,940,497 |
Reported balance
After 2021-07-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-07-09 · Sale · Disposed 4,067 · Balance 3,940,497 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2: The shares were sold as follows: 1,732 by MPM BioVentures 2014, L.P. ("BV 2014"), 60 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,275 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,061,400 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,952 by AM BV2014 and 1,672,302 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 3,883,196 |
Reported balance
After 2021-07-12 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-07-12 · Sale · Disposed 57,301 · Balance 3,883,196 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5: The shares were sold as follows: 24,408 by BV 2014, 838 by AM BV2014 and 32,055 by UBS Oncology. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7: The shares are held as follows: 2,036,992 by BV 2014, 135,843 by BV 2014(B), 70,114 by AM BV2014 and 1,640,247 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 3,882,485 |
Reported balance
After 2021-07-12 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-07-12 · Sale · Disposed 711 · Balance 3,882,485 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8: The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014 and 398 by UBS Oncology. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.055 to $34.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10: The shares are held as follows: 2,036,689 by BV 2014, 135,843 by BV 2014(B), 70,104 by AM BV2014 and 1,639,849 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.
F2: The shares were sold as follows: 1,732 by MPM BioVentures 2014, L.P. ("BV 2014"), 60 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,275 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The shares are held as follows: 2,061,400 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,952 by AM BV2014 and 1,672,302 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5: The shares were sold as follows: 24,408 by BV 2014, 838 by AM BV2014 and 32,055 by UBS Oncology.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The shares are held as follows: 2,036,992 by BV 2014, 135,843 by BV 2014(B), 70,114 by AM BV2014 and 1,640,247 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F8: The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014 and 398 by UBS Oncology.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.055 to $34.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10: The shares are held as follows: 2,036,689 by BV 2014, 135,843 by BV 2014(B), 70,104 by AM BV2014 and 1,639,849 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Entrada Therapeutics, Inc.
Report date September 04, 2026 · Filed September 09, 2026
Jointly reported with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Section 16 reporting ended · disclosed 2026-09-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,106,452 |
Reported balance
After 2026-09-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-09-04 · Sale · Disposed 38,500 · Balance 4,106,452 F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,913,952 |
Reported balance
After 2026-09-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-09-08 · Sale · Disposed 192,500 · Balance 3,913,952 F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018. F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,885,115 |
Reported balance
After 2026-09-09 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-09-09 · Sale · Disposed 28,837 · Balance 3,885,115 F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018. F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.
F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.
F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.
F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.
F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.
TCR2 THERAPEUTICS INC.
Report date June 01, 2023 · Filed June 05, 2023
Section 16 reporting ended · disclosed 2023-06-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-06-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-06-01 · Other · Disposed 304,001 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F3: The shares were held by MPM Asset Management LLC ("AM LLC"). The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-06-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-06-01 · Other · Disposed 3,854,963 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. The reporting person is a managing director of BV LLC and a member of SunStates GP and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-06-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-06-01 · Other · Disposed 3,370,982 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F5: The shares were held by UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. The reporting person is the managing partner of BioImpact and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").
F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").
F3: The shares were held by MPM Asset Management LLC ("AM LLC"). The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. The reporting person is a managing director of BV LLC and a member of SunStates GP and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F5: The shares were held by UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. The reporting person is the managing partner of BioImpact and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Werewolf Therapeutics, Inc.
Report date December 02, 2025 · Filed December 04, 2025
Jointly reported with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Section 16 reporting ended · disclosed 2025-12-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 4,924,566 |
Reported balance
After 2025-12-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-12-02 · Sale · Disposed 59,277 · Balance 4,924,566 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 4,867,341 |
Reported balance
After 2025-12-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-12-03 · Sale · Disposed 57,225 · Balance 4,867,341 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 4,784,111 |
Reported balance
After 2025-12-04 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-12-04 · Sale · Disposed 83,230 · Balance 4,784,111 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.
F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.
F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.
iTeos Therapeutics, Inc.
Report date May 13, 2025 · Filed May 15, 2025
Jointly reported with MPM BIOIMPACT LLC, Oncology Impact Fund (Cayman) Management L.P., UBS Oncology Impact Fund L.P.
Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,452,797 |
Reported balance
After 2025-05-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-05-13 · Sale · Disposed 1,031,931 · Balance 3,452,797 F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.
F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2021 Filed May 6, 2021 20:05 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 59 | $23.09 | $1,362.31 |
DisclosureSEC source: 0001209191-21-030611 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,551,286 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 52 by UBS Oncology and 7 by AM LLC. F6 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 252,457 by AM LLC and 3,392,886 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 05, 2021 Filed May 6, 2021 20:05 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 10,113 | $22.52 | $227,744.76 |
DisclosureSEC source: 0001209191-21-030611 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,551,345 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 8,889 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,224 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.075 to $23.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 252,464 by AM LLC and 3,392,938 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 04, 2021 Filed May 4, 2021 21:43 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 3,500 | $23.33 | $81,655.00 |
DisclosureSEC source: 0001209191-21-029994 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,561,458 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F14 · shares: The shares were sold as follows: 3,076 by UBS Oncology and 424 by AM LLC. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.29 to $23.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F16 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 253,688 by AM LLC and 3,401,827 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 04, 2021 Filed May 4, 2021 21:43 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 26,230 | $23.03 | $604,076.90 |
DisclosureSEC source: 0001209191-21-029994 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,564,958 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F11 · shares: The shares were sold as follows: 23,056 by UBS Oncology and 3,174 by AM LLC. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.29 to $23.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 254,112 by AM LLC and 3,404,903 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:19 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries B Preferred Stock · Derivative | 12,899,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030625 · doc4.xml · derivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,488,033 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F9 · derivative.underlying_shares: The shares were held as follows: 693,667 by BV 2014, 46,266 by BV 2014(B), 23,876 by AM BV2014, 152,083 by MPM OIF and 572,141 by UBS Oncology. F8 · ownership.nature: No securities held by the Reporting Persons. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:19 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries A Preferred Stock · Derivative | 38,817,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030625 · doc4.xml · derivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,477,742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F7 · derivative.underlying_shares: The shares were held as follows: 2,087,358 by BV 2014, 139,224 by BV 2014(B), 71,848 by AM BV2014, 457,643 by MPM OIF and 1,721,669 by UBS Oncology. F8 · ownership.nature: No securities held by the Reporting Persons. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:19 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | PurchaseCommon Stock | 245,000 | $16.00 | $3,920,000.00 |
DisclosureSEC source: 0001209191-21-030625 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,672,183 F5 · shares: The shares were purchased as follows: 114,210 by BV 2014, 7,618 by BV 2014(B), 3,931 by AM BV2014, 25,040 by MPM OIF and 94,201 by UBS Oncology. F6 · ownership.nature: The shares are held as follows: 461,408 by AM LLC, 2,895,235 by BV 2014, 193,108 by BV 2014(B), 99,655 by AM BV2014, 634,766 by MPM OIF and 2,388,011 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:19 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 1,488,033 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-030625 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,427,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · ownership.nature: The shares are held as follows: 461,408 by AM LLC, 2,781,025 by BV 2014, 185,490 by BV 2014(B), 95,724 by AM BV2014, 609,726 by MPM OIF and 2,293,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:19 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 4,477,742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-030625 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,939,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,087,358 by MPM BioVentures 2014, L.P. ("BV 2014"), 139,224 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,848 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 457,643 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 1,721,669 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a member of AM LLC and a Managing Director of BV LLC. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. F3 · ownership.nature: MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:43 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 4,401 | $23.45 | $103,203.45 |
DisclosureSEC source: 0001209191-21-029994 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,591,188 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8 · shares: The shares were sold as follows: 3,868 by UBS Oncology and 533 by AM LLC. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.38 to $23.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 257,286 by AM LLC and 3,427,959 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:43 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 26,365 | $23.03 | $607,185.95 |
DisclosureSEC source: 0001209191-21-029994 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,595,589 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 23,175 by UBS Oncology and 3,190 by AM LLC. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.37 to $23.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 257,819 by AM LLC and 3,431,827 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 30, 2021 Filed May 4, 2021 21:43 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 268,023 | $22.35 | $5,990,314.05 |
DisclosureSEC source: 0001209191-21-029994 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,621,954 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 235,586 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 32,437 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.825 to $22.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 261,009 by AM LLC and 3,455,002 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 29, 2021 Filed Apr 29, 2021 21:46 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 21,781 | $22.54 | $490,943.74 |
DisclosureSEC source: 0001209191-21-029064 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,889,977 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F17 · shares: The shares were sold as follows: 19,145 by UBS Oncology and 2,636 by AM LLC. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.36 to $22.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F19 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 293,446 by AM LLC and 3,690,588 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 29, 2021 Filed Apr 29, 2021 21:46 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 45,511 | $22.02 | $1,002,152.22 |
DisclosureSEC source: 0001209191-21-029064 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,911,758 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F14 · shares: The shares were sold as follows: 40,003 by UBS Oncology and 5,508 by AM LLC. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.32 to $22.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F16 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 296,082 by AM LLC and 3,709,733 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 21:46 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 36,803 | $22.01 | $810,034.03 |
DisclosureSEC source: 0001209191-21-029064 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,957,269 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F11 · shares: The shares were sold as follows: 32,349 by UBS Oncology and 4,454 by AM LLC. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.93 to $22.155 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 301,590 by AM LLC and 3,749,736 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 21:46 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 14,219 | $21.64 | $307,699.16 |
DisclosureSEC source: 0001209191-21-029064 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,994,072 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8 · shares: The shares were sold as follows: 12,498 by UBS Oncology and 1,721 by AM LLC. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.92 to $21.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 306,044 by AM LLC and 3,782,085 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:46 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 8,328 | $21.26 | $177,053.28 |
DisclosureSEC source: 0001209191-21-029064 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,008,291 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 7,320 by UBS Oncology and 1,008 by AM LLC. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.08 to $21.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 307,765 by AM LLC and 3,794,583 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:46 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 3,501 | $20.99 | $73,485.99 |
DisclosureSEC source: 0001209191-21-029064 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,016,619 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 3,077 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 424 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.08 to $21.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 308,773 by AM LLC and 3,801,903 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 20:04 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 555 | $19.48 | $10,811.40 |
DisclosureSEC source: 0001209191-21-027939 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,020,120 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 488 by UBS Oncology and 67 by AM LLC. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.40 to $19.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 309,197 by AM LLC and 3,804,980 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 20:04 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 8,417 | $18.94 | $159,417.98 |
DisclosureSEC source: 0001209191-21-027939 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,020,675 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 7,398 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,019 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $19.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 309,264 by AM LLC and 3,805,468 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 22:07 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 834 | $19.09 | $15,921.06 |
DisclosureSEC source: 0001209191-21-027611 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,029,092 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F15 · shares: The shares were sold as follows: 733 by UBS Oncology and 101 by AM LLC. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.03 to $19.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F17 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 310,283 by AM LLC and 3,812,866 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 22:07 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 21,415 | $18.70 | $400,460.50 |
DisclosureSEC source: 0001209191-21-027611 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,029,926 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F12 · shares: The shares were sold as follows: 18,823 by UBS Oncology and 2,592 by AM LLC. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.03 to $19.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F14 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 310,384 by AM LLC and 3,813,599 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 22:07 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 100 | $20.08 | $2,008.00 |
DisclosureSEC source: 0001209191-21-027611 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,051,341 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F10 · shares: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC. F11 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 312,976 by AM LLC and 3,832,422 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 22:07 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 9,956 | $19.29 | $192,051.24 |
DisclosureSEC source: 0001209191-21-027611 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,051,441 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F7 · shares: The shares were sold as follows: 8,751 by UBS Oncology and 1,205 by AM LLC. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F9 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 312,988 by AM LLC and 3,832,510 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 22:07 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 300 | $20.56 | $6,168.00 |
DisclosureSEC source: 0001209191-21-027611 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,061,397 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 264 by UBS Oncology and 36 by AM LLC. F6 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 314,193 by AM LLC and 3,841,261 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 22:07 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 5,547 | $19.82 | $109,941.54 |
DisclosureSEC source: 0001209191-21-027611 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,061,697 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 4,875 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 672 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.41 to $20.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 314,229 by AM LLC and 3,841,525 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 00:00 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 8,696 | $20.49 | $178,181.04 |
DisclosureSEC source: 0001209191-21-026880 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,067,244 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F14 · shares: The shares were sold as follows: 7,644 by UBS Oncology and 1,052 by AM LLC. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F16 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 314,901 by AM LLC and 3,846,400 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 00:00 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 12,806 | $20.83 | $266,748.98 |
DisclosureSEC source: 0001209191-21-026880 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,075,940 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F11 · shares: The shares were sold as follows: 11,256 by UBS Oncology and 1,550 by AM LLC. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 315,953 by AM LLC and 3,854,044 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 00:00 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 1,000 | $20.06 | $20,060.00 |
DisclosureSEC source: 0001209191-21-026880 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,088,746 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8 · shares: The shares were sold as follows: 879 by UBS Oncology and 121 by AM LLC. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.44 to $20.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 317,503 by AM LLC and 3,865,300 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:00 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 2,362 | $20.08 | $47,428.96 |
DisclosureSEC source: 0001209191-21-026880 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,089,746 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5 · shares: The shares were sold as follows: 2,076 by UBS Oncology and 286 by AM LLC. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.89 to $20.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 317,624 by AM LLC and 3,866,179 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:00 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 13,692 | $19.35 | $264,940.20 |
DisclosureSEC source: 0001209191-21-026880 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,092,108 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2 · shares: The shares were sold as follows: 12,035 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,657 by MPM Asset Management LLC ("AM LLC"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.89 to $19.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 317,910 by AM LLC and 3,868,255 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 20:13 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 400 | $22.68 | $9,072.00 |
DisclosureSEC source: 0001209191-21-026431 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,105,800 F5 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F12 · shares: The shares were sold as follows: 352 by UBS Oncology and 48 by AM LLC. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.63 to $22.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F14 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 319,567 by AM LLC and 3,880,290 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 20:13 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 6,700 | $21.52 | $144,184.00 |
DisclosureSEC source: 0001209191-21-026431 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,106,200 F5 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F9 · shares: The shares were sold as follows: 5,889 by UBS Oncology and 811 by AM LLC. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.25 to $22.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 319,615 by AM LLC and 3,880,642 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 20:13 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 13,528 | $20.72 | $280,300.16 |
DisclosureSEC source: 0001209191-21-026431 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,112,900 F5 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F6 · shares: The shares were sold as follows: 11,891 by UBS Oncology and 1,637 by AM LLC. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $21.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 320,426 by AM LLC and 3,886,531 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 20:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 200 | $29.99 | $5,998.00 |
DisclosureSEC source: 0001209191-21-026433 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,004,368 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 71 by MPM BioVentures 2014, L.P. ("BV 2014"), 2 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 45 by MPM BioVentures 2018, L.P. ("BV 2018"), 1by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 81 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · ownership.nature: The shares are held as follows: 2,068,870 by BV 2014, 128,561 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,210 by AM BV2014, 1,306,654 by BV 2018, 64,705 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 25,787 by AM BV2018 and 2,338,581 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 20:13 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 10,300 | $23.67 | $243,801.00 |
DisclosureSEC source: 0001209191-21-026431 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,126,428 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 12/21/2020. F2 · shares: The shares were sold as follows: 9,939 by MPM BioVentures 2014, L.P. ("BV 2014") and 361 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $24.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by AM BV2014, 322,063 by MPM Asset Management LLC ("AM LLC") and 3,898,422 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:47 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 414 | $31.01 | $12,838.14 |
DisclosureSEC source: 0001209191-21-026256 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,004,568 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F18 · shares: The shares were sold as follows: 147 by BV 2014, 5 by AM BV2014, 93 by BV 2018, 2 by AM BV2018 and 167 by UBS Oncology. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.945 to $31.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F20 · ownership.nature: The shares are held as follows: 2,068,941 by BV 2014, 128,561 by BV 2014(B), 71,212 by AM BV2014, 1,306,699 by BV 2018, 64,705 by BV 2018(B), 25,788 by AM BV2018 and 2,338,662 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:47 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 31,890 | $30.51 | $972,963.90 |
DisclosureSEC source: 0001209191-21-026256 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,004,982 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F15 · shares: The shares were sold as follows: 11,354 by BV 2014, 391 by AM BV2014, 7,171 by BV 2018, 141 by AM BV2018 and 12,833 by UBS Oncology. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F17 · ownership.nature: The shares are held as follows: 2,069,088 by BV 2014, 128,561 by BV 2014(B), 71,217 by AM BV2014, 1,306,792 by BV 2018, 64,705 by BV 2018(B), 25,790 by AM BV2018 and 2,338,829 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 20:47 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | OtherCommon Stock | 15,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026256 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,036,872 F12 · kind: Represents a pro rata in-kind distribution from BV 2014(B) and BV 2018(B) to its respectve limited partners for no consideration. F13 · shares: The shares were distributed as follows: 10,424 shares by BV 2014(B) and 5,246 shares by BV 2018(B). F14 · ownership.nature: The shares are held as follows: 2,080,442 by BV 2014, 128,561 by BV 2014(B), 71,608 by AM BV2014, 1,313,963 by BV 2018, 64,705 by BV 2018(B), 25,931 by AM BV2018 and 2,351,662 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 20:47 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 1,300 | $33.84 | $43,992.00 |
DisclosureSEC source: 0001209191-21-026256 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,052,542 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F9 · shares: The shares were sold as follows: 463 by BV 2014, 16 by AM BV2014, 292 by BV 2018, 6 by AM BV2018 and 523 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 2,080,442 by BV 2014, 138,985 by BV 2014(B), 71,608 by AM BV2014, 1,313,963 by BV 2018, 69,951 by BV 2018(B), 25,931 by AM BV2018 and 2,351,662 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 20:47 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 3,083 | $32.84 | $101,245.72 |
DisclosureSEC source: 0001209191-21-026256 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,053,842 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 1,097 by BV 2014, 38 by AM BV2014, 693 by BV 2018, 14 by AM BV2018 and 1,241 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 2,080,905 by BV 2014, 138,985 by BV 2014(B), 71,624 by AM BV2014, 1,314,255 by BV 2018, 69,951 by BV 2018(B), 25,937 by AM BV2018 and 2,352,185 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 20:47 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 5,295 | $32.07 | $169,810.65 |
DisclosureSEC source: 0001209191-21-026256 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,056,925 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 1,885 by MPM BioVentures 2014, L.P. ("BV 2014"), 65 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,191 by MPM BioVentures 2018, L.P. ("BV 2018"), 23 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 2,131 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 2,082,002 by BV 2014, 138,985 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,662 by AM BV2014, 1,314,948 by BV 2018, 69,951 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 25,951 by AM BV2018 and 2,353,426 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 21:10 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 24,271 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-020512 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,672,838 F3 · kind: Represents a pro rata in-kind distribution from BV 2014(B) to its limited partners for no consideration. F3 · price: Represents a pro rata in-kind distribution from BV 2014(B) to its limited partners for no consideration. F4 · ownership.nature: The shares are held as follows: 2,364,040 by BV 2014, 157,677 by BV 2014(B), 81,372 by AM BV2014 and 2,069,749 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 21:10 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | SaleCommon Shares | 695,000 | $28.18 | $19,585,100.00 |
DisclosureSEC source: 0001209191-21-020512 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,697,109 F1 · shares: The shares were sold as follows: 363,887 by MPM BioVentures 2014, L.P. ("BV 2014"), 12,525 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 318,588 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: The shares are held as follows: 2,364,040 by BV 2014, 181,948 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 81,372 by AM BV2014 and 2,069,749 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:03 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 183,051 | $20.00 | $3,661,020.00 |
DisclosureSEC source: 0001209191-21-010209 · doc4.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner Foley Todd · CIK 0001473930 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,238,306 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 12/21/2020. F2 · shares: The shares were sold as follows: 176,644 by MPM BioVentures 2014, L.P. ("BV 2014") and 6,407 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,667,036 by BV 2014, 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,737 by AM BV2014 and 322,063 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Luke Evnin, Ansbert Gadicke and Todd Foley are the members of BV LLC and Luke Evnin and Anbert Gadicke are the members of AM LLC. F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 23:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 9,400 | $20.25 | $190,350.00 |
DisclosureSEC source: 0001209191-21-008935 · doc4.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner Foley Todd · CIK 0001473930 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,421,357 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 12/21/2020. F9 · shares: The shares were sold as follows: 9,071 by BV 2014 and 329 by AM BV2014. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 2,843,680 by BV 2014, 152,470 by BV 2014(B), 103,144 by AM BV2014 and 322,063 by AM LLC. MPM BioVentures 2014 GP LLC and BV LLC are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Luke Evnin, Ansbert Gadicke and Todd Foley are the members of BV LLC and Luke Evnin and Anbert Gadicke are the members of AM LLC. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 23:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 72,128 | $20.04 | $1,445,445.12 |
DisclosureSEC source: 0001209191-21-008935 · doc4.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner Foley Todd · CIK 0001473930 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,430,757 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 12/21/2020. F6 · shares: The shares were sold as follows: 69,604 by BV 2014 and 2,524 by AM BV2014. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 2,852,751 by BV 2014, 152,470 by BV 2014(B), 103,473 by AM BV2014 and 322,063 by AM LLC. MPM BioVentures 2014 GP LLC and BV LLC are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Luke Evnin, Ansbert Gadicke and Todd Foley are the members of BV LLC and Luke Evnin and Anbert Gadicke are the members of AM LLC. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 23:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 10,172 | $20.01 | $203,541.72 |
DisclosureSEC source: 0001209191-21-008935 · doc4.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner Foley Todd · CIK 0001473930 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,502,885 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 12/21/2020. F2 · shares: The shares were sold as follows: 9,816 by MPM BioVentures 2014, L.P. ("BV 2014") and 356 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.96 to $20.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,922,355 by BV 2014, 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 105,997 by AM BV2014 and 322,063 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Luke Evnin, Ansbert Gadicke and Todd Foley are the members of BV LLC and Luke Evnin and Anbert Gadicke are the members of AM LLC. F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 00:30 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 29,730 | $20.37 | $605,600.10 |
DisclosureSEC source: 0001209191-21-007900 · doc4.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner Foley Todd · CIK 0001473930 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,513,057 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 12/21/2020. F9 · shares: The shares were sold as follows: 28,689 by BV 2014 and 1,041 by AM BV2014. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 2,932,171 by BV 2014, 152,470 by BV 2014(B), 106,353 by AM BV2014 and 322,063 by AM LLC. MPM BioVentures 2014 GP LLC and BV LLC are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Luke Evnin, Ansbert Gadicke and Todd Foley are the members of BV LLC and Luke Evnin and Anbert Gadicke are the members of AM LLC. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 00:30 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 41,922 | $20.21 | $847,243.62 |
DisclosureSEC source: 0001209191-21-007900 · doc4.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner Foley Todd · CIK 0001473930 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,542,787 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 12/21/2020. F6 · shares: The shares were sold as follows: 40,455 by BV 2014 and 1,467 by AM BV2014. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 2,960,860 by BV 2014, 152,470 by BV 2014(B), 107,394 by AM BV2014 and 322,063 by AM LLC. MPM BioVentures 2014 GP LLC and BV LLC are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Luke Evnin, Ansbert Gadicke and Todd Foley are the members of BV LLC and Luke Evnin and Anbert Gadicke are the members of AM LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.